Zimmer Biomet: Growth Acceleration Is Likely Driven By ROSA; Initiate With 'Buy'

Peter Dazeley/The Image Bank via Getty Images Zimmer Biomet (NYSE:ZBH) used to operate under a turnaround business, aiming to close the gap with its major competitor, Stryker (SYK). They spun off their spine and dental divisions and refocused on high-growth areas in knees, hips, extremities, and trauma markets. Zimmer appointed their new CEO, Ivan Tornos, in April 2023, and the management team is currently emphasizing growth acceleration. I am initiating coverage with a 'Buy' rating and a fair value of $140 ...